Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events

Baseline median TMAO level was 20.41 μM in a cohort of 2529 CKD patients.

• Elevated trimethylamine N-oxide (TMAO) levels are independently associated with cardiovascular (CV) events in patients with chronic kidney disease (CKD).
• A hazard ratio of 1.23 indicates a 23% increase in risk for CV events with each standard deviation increase in TMAO.
• Patients in the highest quartile of TMAO had a significantly higher risk of CV events, with an adjusted hazard ratio of 1.59.
• Among stage 3b CKD patients, TMAO levels identified individuals at higher risk for ischemic CV events, with a hazard ratio of 1.45.
• Further studies are needed to explore the variability of TMAO levels and the potential impact of lowering TMAO on CV risk in CKD patients.

AI simplified